Literature DB >> 18401766

Open-label, randomized, multiple-center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus.

Wei-Qing Wang1, Yi-Fei Zhang, Da-Jin Zhou, Zhi-Min Liu, Xu Hong, Ming-Cai Qiu, Yong-Quan Shi, Pei-Jin Xia, Jin Lu, Mao-Jing Xu, Liang An, Wei Feng, Peng Zhang, J Schwamman, Guang Ning.   

Abstract

Since the increase of prevalence of type 2 diabetes mellitus (T-2DM), the replacing quickly absorbed carbohydrates with a fat source rich in monounsaturated fatty acid to provide improved glycemic control in these patients has become an important assistant therapy. In the present study, we compared glycemic response and safety of two nutritional products, Glucerna and Fresubin, in Chinese subjects with T-2DM. Overall, 203 T-2DM subjects were randomly assigned (1:1) to either Glucerna or Fresubin. The primary endpoint was the adjusted area under the curve (adj-AUC) for plasma glucose at 0-240 min. Blood samples were collected at 0, 30, 60, 90, 120, 180, and 240 min to compare the adjusted area under the curve (AUC) for the change in plasma glucose or insulin from 0 to 240 min. Adjusted peak values and times of glucose and insulin responses and adjusted glucose and insulin values were collected at the same time points. Safety parameters were also evaluated. The adjusted AUC for the change in plasma glucose in the Glucerna group was significantly lower than in Fresubin group (5.60 +/- 5.88 mmol/l*h vs. 7.97 +/- 6.32 mmol/l*h, P = 0.0061), as was the adjusted peak value of glucose (3.51 +/- 2.04 mmol/l vs. 4.69 +/- 1.99 mmol/l, P < 0.0001). Glucerna subjects had a longer adjusted peak time to insulin response compared to Fresubin subjects (105.00 +/- 43.4 min vs. 88.81 +/- 37.69 min, P = 0.0050). Glucerna subjects also experienced more gradual changes in glucose and insulin values. In conclusion, Glucerna provided better control of postprandial plasma glucose and insulin levels in Chinese subjects with T-2DM. Variation of postprandial glucose tended to be relatively stable after patients took Glucerna. Study results suggest that Glucerna may be beneficial in the reduction of postprandial glycemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18401766     DOI: 10.1007/s12020-008-9059-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  22 in total

1.  Effect of a nutritional liquid supplement designed for the patient with diabetes mellitus (Glucerna SR) on the postprandial glucose state, insulin secretion and insulin sensitivity in healthy subjects.

Authors:  M González-Ortiz; E Martínez-Abundis; E Hernández-Salazar; A M Kam-Ramos; J A Robles-Cervantes
Journal:  Diabetes Obes Metab       Date:  2006-05       Impact factor: 6.577

Review 2.  Nutrition principles and recommendations in diabetes.

Authors:  Marion J Franz; John P Bantle; Christine A Beebe; John D Brunzell; Jean-Louis Chiasson; Abhimanyu Garg; Lea Ann Holzmeister; Byron Hoogwerf; Elizabeth Mayer-Davis; Arshag D Mooradian; Jonathan Q Purnell; Madelyn Wheeler
Journal:  Diabetes Care       Date:  2004-01       Impact factor: 19.112

3.  Effects of various enteral feeding products on postprandial blood glucose response in patients with type I diabetes.

Authors:  A L Peters; M B Davidson
Journal:  JPEN J Parenter Enteral Nutr       Date:  1992 Jan-Feb       Impact factor: 4.016

4.  High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations.

Authors:  P M Kris-Etherton; T A Pearson; Y Wan; R L Hargrove; K Moriarty; V Fishell; T D Etherton
Journal:  Am J Clin Nutr       Date:  1999-12       Impact factor: 7.045

5.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

Authors:  M Hanefeld; S Fischer; U Julius; J Schulze; U Schwanebeck; H Schmechel; H J Ziegelasch; J Lindner
Journal:  Diabetologia       Date:  1996-12       Impact factor: 10.122

6.  Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease.

Authors:  C M Alexander; P B Landsman; S M Teutsch
Journal:  Am J Cardiol       Date:  2000-11-01       Impact factor: 2.778

Review 7.  Contrast-induced nephrotoxicity: clinical landscape.

Authors:  R W Katzberg; C Haller
Journal:  Kidney Int Suppl       Date:  2006-04       Impact factor: 10.545

8.  A high-monounsaturated-fat/low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin-dependent diabetic patients.

Authors:  M Parillo; A A Rivellese; A V Ciardullo; B Capaldo; A Giacco; S Genovese; G Riccardi
Journal:  Metabolism       Date:  1992-12       Impact factor: 8.694

9.  Carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus: effects of a low-fat, high-carbohydrate diet vs a diet high in monounsaturated fatty acids.

Authors:  A Bonanome; A Visonà; L Lusiani; G Beltramello; L Confortin; S Biffanti; F Sorgato; F Costa; A Pagnan
Journal:  Am J Clin Nutr       Date:  1991-09       Impact factor: 7.045

10.  Effects on blood pressure, glucose, and lipid levels of a high-monounsaturated fat diet compared with a high-carbohydrate diet in NIDDM subjects.

Authors:  O W Rasmussen; C Thomsen; K W Hansen; M Vesterlund; E Winther; K Hermansen
Journal:  Diabetes Care       Date:  1993-12       Impact factor: 19.112

View more
  2 in total

1.  Community-Dwelling Adults at Nutrition Risk: Characteristics in Relation to the Consumption of Oral Nutritional Supplements.

Authors:  Suela Sulo; Linda Schiffer; Patricia Sheean; Isabel Farrar; Jamie Partridge; Marian Fitzgibbon
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

2.  Use of a Low-carbohydrate Enteral Nutrition Formula with Effective Inhibition of Hypoglycemia and Post-infusion Hyperglycemia in Non-diabetic Patients Fed via a Jejunostomy Tube.

Authors:  Shinji Nishiwaki; Hiroko Fujimoto; Takuya Kurobe; Atsushi Baba; Masahide Iwashita; Hiroo Hatakeyama; Takao Hayashi; Teruo Maeda
Journal:  Intern Med       Date:  2020-05-26       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.